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Cerebral malaria (CM) is one of the most severe complications of Plasmodium falciparum
infection. There is evidence that repeated parasite exposure promotes resistance
against CM. However, the immunological basis of this infection-induced resistance
remains poorly understood. Here, utilizing the Plasmodium berghei ANKA (PbA) model
of experimental cerebral malaria (ECM), we show that three rounds of infection and
drug-cure protects against the development of ECM during a subsequent fourth
(4X) infection. Exposure-induced resistance was associated with specific suppression
of CD8+ T cell activation and CTL-related pathways, which corresponded with the
development of heterogeneous atypical B cell populations as well as the gradual
infection-induced generation and maintenance of high levels of anti-parasite IgG.
Mechanistically, transfer of high-titer anti-parasite IgG did not protect 1X infected mice
against ECM and depletion of atypical and regulatory B cells during 4X infection failed
to abrogate infection-induced resistance to ECM. However, IgMi mice that were unable
to produce secreted antibody, or undergo class switching, during the repeated rounds
of infection failed to develop resistance against ECM. The failure of infection-induced
protection in IgMi mice was associated with impaired development of atypical B cell
populations and the inability to suppress pathogenic CD8+ T cell responses. Our
results, therefore, suggest the importance of anti-parasite antibody responses, gradually
acquired, and maintained through repeated Plasmodium infections, for modulating the
B cell compartment and eventually suppressing memory CD8+ T cell reactivation to
establish infection-induced resistance to ECM.
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INTRODUCTION
Malaria remains one of the most prevalent and severe diseases
in the world, responsible for 445,000 deaths, principally in Sub
Saharan Africa, in 2016 (1). The majority of malarial morbidity
and mortality are attributable to a small number of distinct
but frequently overlapping complications, of which, cerebral
malaria is one of the most severe (2, 3). In endemic regions,
children under 5 years of age are disproportionally susceptible
to cerebral malaria whereas older children and adults, despite
often harboring very high parasite burdens, rarely develop severe
disease (4).
It is believed that the age-associated protection from cerebral
malaria in endemic regions is driven by repeated parasite-
exposure, and resultant reprogramming of anti-Plasmodium
immunity, rather than natural evolution of immune components
in the maturing host immune system (5–9). Indeed, adults
remain susceptible to severe malarial disease in non-endemic
malarial areas and in regions of unstable transmission (4).
Nevertheless, the precise number of infectious episodes necessary
to provide immunity to severe malaria has yet to be definitively
defined (10). Moreover, despite substantial research, the nature,
and identity of the immune responses that develop following
natural repeated exposure to prevent cerebral malaria are also
poorly understood (5–9).
Anti-parasite antibodies, Foxp3+ regulatory T cells, IL-
10 secreting T cells, and tolerance to malaria toxins, such
as GPI and hemozoin, have all been postulated to play
important roles in the establishment of immune balance during
malaria; however, how these responses develop and their
relative contribution to infection-induced protection against
severe disease, is mostly unknown (5–9, 11, 12). There is
increasing evidence that atypical B cell populations characterized
by expression of various markers including CD11c and T-bet
develop in response to chronic and repetitious Plasmodium
exposure (13, 14). Nevertheless, the function of atypical B
cells and their influence in regulating resistance to severe
malarial complications remain unclear (13–19). Indeed, whilst
atypical memory B cells have been shown to be superior active
sources of anti-parasite antibody than traditional memory B
cells (15), in other studies they have been shown to exhibit
restricted activation and impaired capacity to differentiate into
antibody or cytokine producing cells following re-stimulation
(13). Atypical memory B also express high levels of regulatory
receptors and may exert important immunoregulatory functions
in suppressing inflammation during malaria, contributing to
anti-disease immunity (14, 17–19).
In this study we have utilized the Plasmodium berghei
ANKA (PbA) murine model of experimental cerebral malaria
(ECM) to examine the immunological basis of exposure-induced
resistance against malarial cerebral pathology. To date, the ECM
model (20) has been significantly underused in the study of
immune mechanisms that provide infection-induced protection
against severe malaria disease. Indeed, the physiological immune
pathways developed following repeated PbA infection that
prevent ECM remain unknown. Here we demonstrate that three
rounds of infection-drug cure are required to promote robust
resistance to ECM during subsequent fourth (4X) infection. We
show that infection-induced resistance to ECM is associated
with the significant expansion of atypical B cell populations
and repression of memory CD8+ T cell reactivation, and that
this protection is abrogated in mice unable to produce secreted
antibody, or undergo class switching. Protection, however,
cannot be recapitulated in primary infected mice following
passive transfer of plasma from resistant repeatedly infected
mice. Moreover, protection is intact in repeatedly infected
mice in which atypical and regulatory B cells are acutely
depleted. The results in this study provide new evidence for
the importance of antibody in mediating protection against
cerebral malaria and suggest antibody is required throughout and
post-repeated infections to orchestrate gradual modulations in
immune responses that ultimately underpin protection.
MATERIALS AND METHODS
Mice and Infections
6–8 week old C57BL/6 mice were purchased from Charles
River. IgMi mice (21, 22) and littermate WT mice were bred
at the University of Manchester. All mice were maintained in
individually ventilated cages at the University of Manchester.
BALB/c mice were used for production of P. berghei parasite
lysate at theUniversity of Oxford. CryopreservedGFP-expressing
P. berghei ANKA parasites of clone 15cy1 (23) were thawed and
passaged through mice before being used to infect experimental
mice via intravenous (i.v.) injection of 1 × 104 parasitized
red blood cells (pRBCs) in the tail vein. Infected mice
were monitored for neurological symptoms (paralysis, ataxia,
convulsions, and coma occurring between day 6 and 10 post-
infection). Parasitemia was measured from day 3 post-infection
(p.i.) by examination of Giemsa-stained thin blood. Drug cure
was achieved on specified days by six, daily, intraperitoneal (i.p.)
injections of 30 mg/kg chloroquine combined with 30 mg/kg
artesunate in PBS. In some experiments mice were administered
on indicated days of 4X infection, via intraperitoneal (i.p.)
injection, 300 µg anti-IL-10R (1B1.3A), 250 µg anti-CD20mAb
(5D2), or 250 µg anti-Ragweed (control) mAb (Abs from
Bioxcell or Genentech, Inc.). In some experiments mice were
administered on indicated days of 1X infection, via i.p. injection,
500 µl of heat inactivated plasma (heated at 56◦C for 30min
to destroy cytokines and complement), obtained from 4X
infected mice (day 7/8 of infection) or from age matched naïve
mice. ECM development was assessed using a well-established
grading system (24): 1=no signs; 2=ruffled fur/and or abnormal
posture; 3=lethargy; 4=reduced responsiveness to stimulation
and/or ataxia and/or respiratory distress/hyperventilation; 5=
prostration and/or paralysis and/or convulsions. Stages 2–3 were
classified as prodromal signs of ECM and stages 4–5 were
classified as late stage ECM. All animals were euthanized by rising
concentration of CO2 when observed at stage 4 or 5.
RNA Isolation
Spleen sections were isolated from mice prior to whole-body
perfusion of PBS. Brains were isolated from mice following
intracardial whole-body perfusion of PBS. Tissue was snap
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frozen in liquid nitrogen and stored at −80◦C until use. RNA
isolation from spleen sections and whole brains was performed
by homogenizing brains in Trizol and using lipid tissue RNA easy
kits according to the manufacturer’s instructions (RNeasy Lipid
Tissue Mini Kit, Qiagen). Isolated RNA was DNase treated to
remove genomic DNAprior to QC analysis and use inmicroarray
or NanoString analysis.
Microarray and Gene Expression Analysis
The global gene expression profiles of brains from uninfected,
1X infected, post-3X infected mice and 4X infected mice
were probed using the Affymetrix GeneChip R© Mouse Genome
430 2.0 microarray containing 34,000 genes. Technical quality
control and outlier analysis was performed with dChip (V2005)
[www.dchip.org: (25)] using the default settings. Background
correction, quantile normalization, and gene expression analysis
were performed using RMA in Bioconductor (26). To establish
relationships and compare variability between samples, principal
components analysis (PCA) was used as this method reduces
the effective dimensionality of complex gene-expression space
without significant loss of information (27). PCA was performed
with Partek Genomics Solution (version 6.5, Copyright 2010,
Partek Inc., St. Charles, MO, USA). Differential expression
analysis was performed using Limma using the functions lmFit
and eBayes (28). 1,957 probe-sets were identified by pairwise
comparisons (fold change < or > 1.5 and qvalue < 0.05)
between 1X infected vs. uninfected and/or 4X infected vs. aged
uninfected groups. The expression level of each probeset was
normalized to the naïve average (in log scale, the naïve average
expression was calculated and subtracted from each expression
level), and then the standard deviation was normalized to 1
(expression level was divided by the standard deviation). The
differentially expressed probesets were ranked by clustering
the mean expression levels in each group (expression in each
group normalized by z-transformation of the mean in log scale),
by k-means clustering into 5 clusters, and then ranked by
hierarchical clustering. Gene ontology analysis was performed
using DAVID Functional Annotation Bioinformatics Microarray
Analysis database.
Nanostring Analysis
The nCounter Gene Expression assay (Nanostring Technologies,
Seattle, USA) was performed according to the manufacturer’s
instructions. Transcript counts were normalized to the relevant
housekeeping genes using the nSolver Analysis Software (vers.
2.5; Nanostring Technologies).
Flow Cytometry
Spleens were mashed and cell suspensions were generated by
homogenizing tissue through a 70µm cell sieve (BD Biosciences)
and subjected to RBC lysis (BD Bioscience). Brains were finely
minced and leukocytes isolated using the single-step percoll
method (29). Cell pellets were subjected to a RBC lysis step.
Absolute cell numbers were determined by microscopy using
a haemocytometer and live/dead differentiation was performed
using the trypan blue exclusion cell viability assay (Sigma).
Isolated leukocytes were surface stained with anti-mouse CD3
(17A2), CD4 (GK1.5), CD8 (53-6.7), CD11c (N418), CD19 (6D5
or 1D3), CD45 (30-F11), CD62L (MEL-14), CD80 (16-10A1),
CD138 (281-2), ICOS (15F9 or C398.4A), KLRG1 (2F1), IgD (11-
26c.2a), IgM (RMM-1), MHC II (M5/114.15.2), PDCA-1 (927),
and PDL-1 (MIH5 or 10F.9G2). Intracellular staining for Foxp3
(FJK-16s), granzyme B (GB11), IFNγ (XMG1.2), Ki67 (SolA15)
and Tbet (4B10) was performed, after treatment with Foxp3
fixation/permeabilisation buffer (eBioscience). IFNγ staining was
performed following 4 h in vitro stimulation of splenocytes
with 50 ng/mL PMA / 2.5 ug/mL ionomycin. Dead cells were
excluded using LIVE/DEAD R© Fixable Blue Dead Cell Stain Kit
(Life Technologies). Fluorescence minus one (FMO) controls
were used to set gates. Cells were analyzed with a BD LSR II
or Fortessa (Becton Dickinson) using BD FACSDiva software
(Becton Dickinson). Data were analyzed with FlowJo (Tree Star
Inc.). All antibodies were from eBioscience and Biolegend.
Histology
Brains were processed and stained with Haematoxylin/Eosin
(H & E) as described (17). Briefly, brains were isolated from
mice perfused with PBS followed by 4% paraformaldehyde (pfa).
Brains were stored in 20% sucrose/4% pfa for 24 h at (4◦C)
before being transferred to 20% sucrose/PBS for a further 24 h
(4◦C). Coronal sections were cut using a sledge-microtome at
a thickness of 30µm. Sections were mounted and stained with
Haematoxylin/Eosin.
Immunofluorescence
Brain sections were stained with anti-GFP (A-21311, Life
Technologies) and anti-CD31 (MEC 13.3, BD Pharmingen) as
described (20). Sections were counterstained in DAPI (Sigma-
Aldrich) then cover-slipped in ProLong Diamond anti-fade
Mountant (Life Technologies).
ELISA
Serum anti-P. berghei merzoite surface protein 1 C-terminal
19 kDa region (PbMSP119) and anti-P.berghei ANKA antibody
endpoint titers were determined as previously described (30),
Briefly, 96 well ELISA plates (Thermo Scientific) were coated
with PbMSP119-glutathione S-transferase (GST) fusion protein
[0.5µg/ml] or P.berghei ANKA blood-stage parasite lysate,
generated as previously described (31) [0.5µg/ml], respectively,
before being incubated overnight at 4◦C, blocked with PBS with
1% BSA at 37◦C for 1 h, and diluted mouse sera added in
duplicate wells. Plates were incubated at 37◦C for 2 h before
antibodies were detected using alkaline phosphatase conjugated
goat anti-mouse total IgG (Sigma-Aldrich) (1:3,000) for 1 h
at 37◦C and developed with p-nitrophenylphosphate (Sigma-
Aldrich) with absorbance readings at taken at OD405nm. Anti-
GST responses were obtained by running concurrent wells
coated with GST protein [0.29µg/ml] and subtracted from the
respective PbMSP1-GST OD405nm readings. Endpoint titers were
determined as the calculated dilution at which the OD405nm
equaled no sera control wells for anti-parasite, and zero for the
GST subtracted anti-PbMSP119 ELISA.
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Quantification of Plasma Cytokine Levels
The concentrations of IL-2, IFN-γ, TNF, and IL-10
in plasma were measured using a ProcartaPlex Mouse
Cytokine & Chemokine Panel (26 plex) (eBioscience)
on a Luminex R© 100/200TM System, following the
manufacturer’s instructions.
Statistical Analysis
All statistical analyses were performed using GraphPad PRISM
(GraphPad Software, USA). Data were tested for normality using
the Shapiro-Wilk normality test. For normally distributed data,
comparisons between two groups were made using a Student’s t-
test, with Welch’s correction and between multiple groups using
a one-way ANOVA with Tukey’s test for multiple comparisons.
For non-parametric data, comparisons between two groups
were made using a Mann-Whitney test and between multiple
groups using a Kruskal-Wallis with Dunn’s test for multiple
comparisons. N-numbers in figure legends refer to the number
of biological replicates used to generate the data shown in
the figure.
RESULTS
Repeated Cycles of Infection and
Drug-Cure Protects Mice Against ECM
To recapitulate the natural repeated Plasmodium falciparum
infections experienced by humans in endemic regions (10)
we adapted the established PbA model of ECM (Figure 1).
C57BL/6 mice were infected with PbA and treated with
anti-malarial drugs (artesunate, the front line treatment for
severe malaria and chloroquine, as a representative quinolone-
containing drug) prior to the development of fulminant
ECM (on day 5 or 6, depending upon infection cycle)
(experimental schematic in Figure 1A). This cycle of infection-
drug cure was repeated up to three times, with a minimum
interval of 30 days between cessation of drug treatment and
reinfection. Mice gradually acquired resistance to ECM, with
mice experiencing a fourth infection (4X infected) being highly
resistant to cerebral complications, which typically developed
between 6 and 8 days post-infection (Figure 1B). Repeatedly
infected mice also gradually acquired a degree of parasite
control as 4X infected mice exhibited reduced parasite burdens
compared with other infected groups during the early phase of
infection (Figure 1C); however, many of the mice subsequently
developed transient high level peripheral parasite burdens,
which were cleared in 80% of mice by day 30 of infection
(Figure S1A and Supplementary Table 1). As expected, very few
histopathological features of ECM [as defined in [20]], were
observed in qualitative analyses of brains from 4X infected
mice, in contrast to evidence of pRBC accumulation (left
panel), hemorrhage (middle panel) and blocked vessels (right
panel) observed in brains from 1X infected mice (Figure 1D
and Figure S1B).
This model, therefore, mimics the gradual, infection-induced
resistance to cerebral malaria seen in humans, in which
resistance to cerebral pathology corresponds with reduced
parasite accumulation in the brain and partial, albeit incomplete,
control of patent peripheral parasitaemia.
Repeated Parasite Exposure Regulates
Intracerebral CD8+ T Cell Activity
Brain migrating CD8+ T cells play a major role in the
pathogenesis of ECM (32). Thus, we investigated whether
infection-induced resistance to ECM was associated with
the attenuation of intracerebral CD8+ T cell responses.
As anticipated, the numbers of CD8+ T cells were
reduced in the brains of 4X infected mice (day 8: no
ECM) compared within brains of 1X infected mice (day
8: late stage ECM) (Figures 2A,B). Moreover, CD8+ T
cells displayed a less activated phenotype in the brains
of 4X infected mice compared with 1X infected mice, as
evidenced by significantly lower expression of granzyme
B (Figures 2C,D).
To assess the potential intracerebral events that led to reduced
CD8+ T cell recruitment and CTL functionality in 4X infected
mice, we contrasted the transcriptome of whole brains from
1X infected mice, from 4X infected mice, and from uninfected
mice. Brains from the three different groups (from day 8 of
both 1X and 4X infection) exhibited distinct transcriptional
signatures (Figures 2E,F). Genes differentially expressed in
brains of 1X infected or 4X infected mice compared with brains
from uninfected mice clustered into 5 distinct clusters, with
various different biological pathways relating to immune system
activation and function being enriched in each cluster (Figure S2,
Supplementary Table 2).
Filtering the dataset in Figure S2 (i.e., the genes differentially
expressed in brains of 1X or 4X infected mice compared
with naïve mice) further, we identified the genes that were
also differentially expressed specifically in brains of 4X
compared with 1X infected mice (1402 genes in total:
Supplementary Table 3). These filtered genes were significantly
enriched within immunological processes that included defense
response, regulation of apoptosis, chemotaxis, CTL activity,
antigen processing and presentation, and cell adhesion (selected
genes in the biological processes are presented in Figure 2G
and full pathways are presented in Figure S2). In general, the
majority of the pro-inflammatory genes (including IL-6 and
IFN-γ gene networks) were expressed at higher levels in brains
from 1X infected compared with 4X infected mice (Figure 2G
and Figures S2, The differences in expression of key genes
involved in antigen processing and presentation, chemotaxis and
CTL activity was verified by NanoString analysis (Figure S3).
Importantly, the brain transcriptome in pre-4X infected mice
(i.e., mice that had undergone three rounds of PbA infection and
drug cure but did not receive a further infection) was almost
identical to that observed in uninfected mice (Figures 2H,I).
Combined, these results show that exposure-induced
resistance to ECM is associated with both the reduction in CD8+
T cell accumulation and CD8+ T cell cytolytic activity within
the brain. Moreover, transcriptional differences in the brain are
only apparent during active infection, and are not maintained
between infections.
Frontiers in Immunology | www.frontiersin.org 4 February 2019 | Volume 10 | Article 248
Shaw et al. Infection-Induced Resistance to ECM
FIGURE 1 | Three rounds of infection-drug cure promote resistance to ECM in susceptible C57BL/6 mice. (A) Schematic of the experimental design. C57BL/6 mice
were infected with PbA (104 pRBCs i.v.) or left uninfected. Mice were treated (i.p.) with chloroquine and artesunate on stated days post each infection, and
re-infections were performed after a minimum interval of 30 days following cessation of drug treatment. (B) Kinetics of ECM development shown as percentage of
survival of mice. N = 7–10 per group, pooled from two independent experiments. (C) Peripheral parasitaemia (% of pRBCs) ± SD in different infection groups. N =
5–9 per group. Results are pooled from two experiments for the 1X, 2X, and 3X infection and from 3 experiments for the 4X infection. Kruskal-Wallis test with Dunn’s
multiple comparisons test was used for statistical analysis p < 0.05 denoted by #, for 1X v 3X, ‡ for 1X v 4X, and ∼ for 2X v 4X. (D) Representative H & E stained
cortical brain sections demonstrating presence (in 1X infected mice) and absence (in 4X infected mice) of cerebrovascular pRBCs (filled arrow), hemorrhage (unfilled
arrow) and leukocyte packed vessels (arrow head) in 1 and 4X infected mice on day 8 post infection. Scale bar 100µm.
Exposure-Induced Resistance to ECM Corresponds
With Specific Inhibition of Splenic CD8+ T Cell
Cytolytic Capacity and Not Generalized Suppression
of Splenic Effector T Cell Responses
The absence ofmaintained transcriptional alterations in the brain
between infections suggested that infection-induced protection
might be controlled at the site of T cell priming, namely the
spleen. We therefore examined splenic T cells responses in 1X
and 4X infected mice. The numbers of splenic CD8+ and CD4+
T cells were significantly increased in 4X infected mice compared
with 1X infected mice on day 8 of infection, contributing
to splenomegaly in 4X infected mice (Figures 3A–D). T cell
numbers were not significantly raised in pre-4X infected mice
compared with uninfected or 1X infected mice, showing that
expansion of the lymphocyte populations occurred rapidly
during the active fourth infection (Figures 3A–C).
Despite their significant expansion, CD8+ T cell activation
and effector function was significantly attenuated in 4X
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FIGURE 2 | 4X PbA infected mice have a distinct whole brain transcriptional signature (A–D) Perfused whole brains were removed from 4X infected and age-matched
1X infected C57BL/6 mice on day 8 p.i. (when 1X developed ECM), and age-matched naïve mice. (A) Representative flow cytometric plots showing identification of
and (B) numbers of CD8+ T cells in the brain (mean ± S.D.). (C) Representative flow cytometric plots showing granzyme B expression by and (D) frequencies of
granzyme B expressing CD8+ T cells in the brain (mean ± S.D.). (A,C) Numbers denote the percentage of cells within the gate. (B,D) N = 4–8 per group, pooled
from two independent experiments. Statistical analyses were performed with Kruskal-Wallis test with Dunn’s multiple comparisons test or with one-way ANOVA with
Tukey’s test, depending on normality of data (*p ≤ 0.05 and ***p ≤ 0.001). (E–G) Microarray analysis was performed on perfused whole brains from 4X infected and
age-matched 1X infected C57BL/6 mice on day 8 p.i. (when 1X developed ECM), and age-matched naïve mice. (E) Principal components analysis of whole-brain
transcriptomes. N = 6 per group. Results are generated from the pooled array data from brains taken from two independent experiments. (F) Venn diagrams defining
unique and overlapping genes differentially expressed between 4X infected vs. uninfected mice and 1X infected mice vs. uninfected mice. (G) Genes in (F) and
Supplementary Figure 2 were filtered to identify genes differentially expressed in brains of 1 and 4X infected mice on day 8 of infection. Heat maps showing
differentially expressed genes grouped by enriched biological processes identified within DAVID bioinformatics database. Results (n = 6 per group) are generated from
the pooled array data from brains taken from two independent experiments. (H,I) Perfused whole brains were removed from pre-4X infected mice (minimum 30 days
post clearance of 3X infection) and age-matched uninfected mice for microarray analysis. (H) Principal components analysis of whole-brain transcriptomes (n = 6 per
group). Results are generated from the pooled array data from brains taken from two independent experiments. (I) Scatter plot comparing gene expression between
pre-4X infected mice and uninfected mice. Each data point represents the mean expression level of a gene. Results (n = 6 per group) are generated from the pooled
array data from brains taken from two independent experiments.
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FIGURE 3 | 4X infected mice develop significantly altered splenic CD8+ and CD4+ T cell responses. (A–H) Spleens and plasma were removed from 4X infected and
age-matched 1X infected C57BL/6 mice on day 8 post-infection (when 1X infected mice developed ECM), from pre-4X infected C57BL/6 mice (minimum 30 days
post clearance of 3X infection), and age-matched uninfected mice. (A) Representative flow cytometric plots and the frequencies of splenic CD8+ T cells and CD4+ T
cells, gated on live CD45+ CD3+ cells. Total numbers of splenic (B) CD8+ T cells, (C) CD4+ T cells and (D) CD45+ cells. (E,F) Representative flow cytometric plots
and the frequencies of splenic (E) CD8+ T cells and (F) CD4+ T cells expressing markers of activation, function and differentiation. (G) Nanostring analysis of gene
expression in whole spleen tissue from 4X and 1X infected mice (on day 8 of infection), expressed relative to gene expression in age-matched uninfected mice (fold
change of 1 defines level of gene expression in uninfected mice). (H) Cytokine bead array of plasma cytokine levels in 4X, 1X infected mice and aged matched
uninfected C57BL/6 mice. (A,E,F) Numbers denote the percentage of cells within the gate. (B–G) Results are the mean ± SD of the group, representative of two
independent experiments with (B–D) n = 3–6 per group, (E,F) n = 3–10 per group and (G) n = 3 per group. (H) N = 4–7 per group, pooled from two independent
experiments. (B–F,H) Statistical analyses were performed with Kruskal-Wallis test with Dunn’s multiple comparisons test or with one-way ANOVA with Tukey’s test,
depending on normality of data (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001). (G) Statistical analysis by Student’s t-test, with Welch’s correction (*p ≤ 0.05).
infected mice compared with 1X infected mice, as shown by
reduced expression of granzyme B, ICOS and Ki67 (Figure 3E).
Interestingly, however, the frequencies of splenic CD8+ T cells
expressing T-bet and IFN-γ were similar in 4X and 1X infected
mice (Figure 3E). In contrast, the activation and differentiation
of splenic CD4+ T cells was generally unaltered in 4X infected
mice compared with 1X infected mice, with only a minor
reduction in Ki67 and upregulation in ICOS expression by CD4+
T cells in 4X infected mice (Figure 3F). The frequencies of
CD4+ T cells expressing Foxp3 was not significantly different
in 4X and 1X infected mice, suggesting that altered regulatory
T cell development was not the major reason for suppression
of CD8+ T cell activity and prevention of ECM in 4X infected
mice (Figure 3F).
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Studying the splenic and systemic immune signature in
4X infected mice compared with 1X infected mice in more
detail revealed that the gene expression of granzyme B and
granzyme A was significantly reduced in 4X infected mice
compared with 1X infected mice (examining gene expression
in whole spleen tissue), whereas there was no significant
differences in expression of 25 other immune response genes,
including antigen presenting molecules (TAP-1, MHC-1), pro-
inflammatory chemokines (CXCL9, CXCL10, CCL2, CCL5), and
cytokines (TNF, IFN-γ, LT-α) (Figure 3G). Moreover, plasma
levels of TNF, IFN-γ and IL-2 were comparable or higher in 4X
infected mice than in 1X infected mice (Figure 3H).
Collectively, our results, therefore, show that infection-
induced resistance to ECM was associated with the specific
reduction in splenic CD8+ T cell cytotoxic functions and
granzyme expression, rather than non-selective suppression of
adaptive T cell expansion and activation, or general dampening
of inflammation.
Infection-Induced Resistance Is Associated With
Generation of Heterogeneous Atypical and
Regulatory B Cell Populations and Improved
Anti-parasite Ab Responses
Chronic and repetitive P. falciparum infection is associated with
the development of atypical B cell populations, the functions
of which are still debated (13–19). As well as being potentially
important sources of anti-parasite Ab (15), they may also
exert immune regulatory activity, suppressing inflammation (14,
17–19). Consequently, we investigated whether repeated PbA
infection led to the formation of atypical B cell populations
and how this may contribute to infection-induced resistance
to ECM. The numbers of splenic CD19+ B cells were
significantly increased in the 4X infected mice compared
with 1X infected mice, examined on day 8 of infection
(Figures 4A,B). Whilst there was a large increase in the
frequencies of CD19+CD138+ (putatively plasmablasts) and
CD19+CD80+ [activated andmemory B cells (33)] in 4X infected
mice compared with 1X infected mice, we also observed an
increase in the frequencies of atypical CD19+ cells expressing
CD11c [B cells that exert APC activity and may contribute to
autoimmunity (13, 34–36)], PDCA-1 [suppressor B cells but
which also produce Abs (37)] and PDL-1 [putatively regulatory
B cells (38)] in 4X infected mice compared with 1X infected
mice (Figure 4C).
The frequencies and numbers of class-switched IgD−IgM−
B cells were also significantly increased in 4X infected
mice compared with 1X infected mice (Figure 4D), which
corresponded with significantly higher plasma titers of anti-
PbMSP119 and total anti-PbA IgG antibodies in 4X infected
mice than 1X infected mice (Figures 4E,F). Of interest, total
anti-PbA Ab responses developed much more gradually upon
repeated infections than anti- PbMSP119 Ab responses (which
largely peaked during 2X infection when mice were still
highly susceptible to ECM), (Figures 4E–G). The levels of anti-
PbMSP119 IgG were not boosted at all during the fourth infection
(when measured on day 8 of infection and compared with
levels in pre-4X infected mice), whereas the levels of total PbA-
specific IgG were boosted only slightly during the 4th infection
(Figures 4E–G).
Thus, infection-induced resistance was associated with the
generation of a heterogeneous B cell response and elevated anti-
parasite IgG production, suggesting potential roles for atypical
and/or regulatory B cells in promoting resistance to ECM.
Individual and Transitory Manipulation of Antibody
and Atypical B Cell Populations Does Not Alter
Resistance or Susceptibility to ECM
To examine the importance of atypical B cell populations
in infection-induced resistance to ECM, we treated mice
immediately prior to and during 4X infection with anti-
CD20mAb (to enable pan-B cell depletion). This approach was
necessary due to the spectrum of cell populations that express
atypical B cell markers, precluding the use of other specific
antibody-targeting approaches. Anti-CD20 mAb depleted nearly
all CD19+ B cells in 4X infected mice (Figure 5A); including
the majority of class switched CD19+ B cells (Figure 5B).
However, as previously reported (39), treatment had less of
an effect on CD19−CD138+ plasma cells than on putative
regulatory and antigen-presenting B cells (including CD19+PD-
L1+, CD19+CD11c+, CD19+PDCA-1+, and CD19+MHC-II+ B
cells), CD19+CD138+ plasmablasts and CD19+CD80+ activated
/ memory cells (Figure 5C). Nevertheless, despite the depletion
of the majority of the B cell compartment, anti-CD20 mAb
treatment did not increase the activation or function of splenic or
intracerebral CD8+ T cells during 4th infection (Figures 5D,E),
with granzyme B expression by CD8+ T cells in anti-CD20mAb
and control Ab treated 4X infected mice being significantly lower
than in 1X infection (Figure S4). Consequently, anti-CD20 mAb
administration did not alter the resistance of 4X infected mice
to ECM (Figures 5F,G). In agreement with this, blockade of IL-
10 activity, a major mechanism of Breg suppression (38), did not
reverse the resistance of 4X infected mice to ECM (Figure S4).
This is despite the fact that IL-10 plasma levels trended higher in
4X infected mice compared with 1X infected mice (Figure S4),
and adoptive transfer of IL-10 producing Bregs from repeatedly
infected mice has previously been shown to promote resistance
to ECM in primary infected mice (40).
The apparent redundancy of infection-induced atypical B cells
(and other B cell populations) in actively mediating infection-
induced resistance to ECMduring the 4X infection suggested that
circulating anti-parasite antibody (which was maintained at high
level in pre-4X infected mice; Figures 4E,F), may be sufficient
to confer protection against ECM. To investigate whether this
was the case, we performed a passive transfer experiment
by transferring plasma from 4X infected mice containing
high titres of anti-parasite IgG (defined in Figures 4E,F) into
mice during the course of 1X infection. Despite significantly
lowering peripheral parasite levels during the early phases of 1X
infection, passive transfer of plasma obtained from repeatedly
infected mice (through 4 separate injections during the course
of infection) failed to protect 1X infected mice from ECM
(Figures 5H,I), or reduce CD8+ T cell activation within the
spleen or brain (Figures 5J,K). Consequently, high levels of
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FIGURE 4 | Anti-parasite IgG titres and atypical B cell populations are significantly increased in 4X infected mice. (A–G) Spleens and plasma were obtained from 4X
infected and age-matched 1X infected C57BL/6 mice on day 8 post-infection (when 1X infected mice developed ECM), from pre 4X infected mice (minimum 30 days
post-clearance of 3X infection) and from age-matched uninfected mice. (A) Representative flow cytometric plots and the frequencies of splenic CD19+ B cells, gated
on live CD45+ CD3− cells. Numbers denote the percentage of cells within the gate. (B) Total numbers of splenic CD19+ B cells. (C) Expression of CD138, CD80,
CD11c, PDCA1, PDL-1, and MHC II by CD19+ splenic B cells from uninfected, 1X infected and 4X infected mice. (D) Left, Representative flow cytometric plots (gated
on live CD45+CD3−CD19+ cells), right, the frequencies and numbers of non-switched (IgM+ IgD+ and IgM− IgD+) and switched (IgM+ IgD−, and IgM− IgD−) splenic
CD19+ B cells. The end point plasma titres of (E) anti- PbMSP119 and (F) anti-PbA IgG, with background titer from naïve mice subtracted. (G) Graphical
representation of the fold change in Ab titer between 1X and 2X infected mice and between 2X and 4X infected mice. (B,D) N = 2–6 per group, representative of two
independent experiments (mean ± SD). Statistical analyses were performed with Kruskal-Wallis test with Dunn’s multiple comparisons test *p ≤ 0.05, **p ≤ 0.01, and
p < 0.05 denoted by #, ∼,
†
for indicated groups. (E,F) N = 6 per group, pooled from two independent experiments (mean ± SD). Statistical analyses were performed
by one-way ANOVA with Tukey’s multiple comparisons test, shown for 4X infected mice compared to each other group (****p ≤ 0.0001).
anti-parasite antibody did not appear to be sufficient to confer
protection against ECM.
Mice Unable to Produce Secreted Antibody Fail to
Acquire Infection-Induced Resistance to ECM
The above results suggested that anti-parasite Ab may not be
sufficient for active protection against ECM when given acutely
during a primary infection. Antibody can directly and indirectly
coordinate many events within the immune system, potentially
influencing long-term immunity and controlling the nature
of immune responses during challenge infections (41–44). As
such, we reasoned that antibody may need to be produced
and maintained during the initial rounds of PbA infection to
condition (or educate) the immune system in repeatedly infected
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FIGURE 5 | Ablation of B cell populations or transitory boosting of anti-parasite antibody does not alter dynamics of ECM in 1X or 4X infected mice. (A–G) C57BL/6
mice were injected (i.p) one day prior to 4X infection and on days 2, 5, 8, 11 of infection, with either (250 µg) anti-CD20 mAb or (250 µg) control anti-ragweed mAb.
(A) Total numbers of splenic CD19+ B cells. (B) Left, Representative flow cytometric plots (gated on live CD45+CD3−CD19+ cells), right, the frequencies of
non-switched (IgM+ IgD+ and IgM− IgD+) and switched (IgM+ IgD−, and IgM− IgD−) splenic CD19+ B cells. (C) Total numbers of splenic CD19− CD138+ plasma B
cells and splenic CD19+ B cells expressing CD138, CD80, CD11c, PDCA1, PDL-1, and MHC II in 4X infected mice that received anti-CD20 mAb or anti-ragweed
mAb. (D,E) The frequencies of Granzyme B expressing CD8+ T cells in the (D) spleen and (E) brain in 4X infected mice that received anti-CD20 mAb or anti-ragweed
mAb. (F) Survival of 4X infected mice given anti-CD20mAb or control mAb. (G) Parasitaemia (% of pRBCs) of 4X infected mice given anti-CD20mAb or control mAb.
(H–K) C57BL/6 mice received 500 µl of heat-inactivated plasma (obtained from 4X infected mice or, as a control, from age-matched naïve mice) prior to and during
1X infection (4 i.p. injections between day −1 and day 5 of infection). (H) Peripheral parasitaemia (% of pRBCs) in 4X infected mice that received plasma from 4X or
uninfected mice (I) Kinetics of ECM development shown as percentage survival of 1X infected mice that received plasma from 4X or uninfected mice. (J,K) The
frequencies of granzyme B expressing CD8+ T cells in the (J) spleen and (K) brain in 1X infected mice that received plasma from 4X or naïve mice. (A–K) Results are
the mean ± SD of the group. (A–C) N = 3–4 per group, representative of two independent experiments. (D,E) N = 7–8 per group, pooled from two independent
experiments. (F, G) N = 10–13 per group, pooled from two independent experiments. (H, I) N = 6–7 per group, pooled from two independent experiments. (J,K) N =
4, representative of two independent experiments. Statistical analyses were performed with by Student’s t-test, with Welch’s correction or Mann-Whitney test
depending on normality of data (*p ≤ 0.05, **p ≤ 0.01 ***p ≤ 0.001 and p < 0.05 denoted by #, ∼, ‡ for indicated groups).
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mice, eventually promoting resistance to ECM in 4X infected
mice. To investigate if this hypothesis was correct, we used IgMi
mice, which contain B cells that are able to produce membrane
IgM but are unable to make secreted antibody or undergo class
switching (21, 22), As expected, no anti- PbMSP119 or total anti-
PbA IgG was detected in the plasma of 4X infected IgMi mice.
Importantly, and in contrast to littermate WT mice, 4X infected
IgMi mice failed to acquire complete or even partial resistance
to ECM, with 100% (8/8) of mice developing accelerated late-
stage ECMbetween days 6 and 7 p.i. (Figure 6A). Parasite control
was reduced but not completely abrogated in 4X infected IgMi
mice compared with 1X infected IgMi mice and 4X infected WT
mice (Figure 6B).
As expected, essentially all CD19+ B cells in IgMi mice
expressed IgM, but not IgD, during 1X infection and this
expression pattern did not change during 4X infection
(Figure 6C). Interestingly, although redundant for active
resistance during 4X infection in WT mice, the development of
atypical and/or regulatory CD11c+, PDCA-1+ and PDL-1+ B
cell populations, as well as CD138+ and CD80+ populations,
were abrogated in 4X IgMi mice (Figure 6D), indicating that
infection-induced development of atypical B cell populations
during malaria was dependent upon secreted antibody.
Splenic CD8+ T cell responses were significantly increased
in 4X IgMi mice compared with 4X infected WT mice,
as demonstrated by the significantly increased frequencies
of CD8+ T cells expressing granzyme B, ICOS, Ki67, and
KLRG1 in 4X infected IgMi mice compared with 4X infected
WT mice (Figure 6E). Moreover, the frequencies of CD8+
T cells expressing granzyme B were higher in the brains
of 4X infected IgMi mice compared with 4X WT mice
(Figure 6F). Interestingly, despite lower peripheral parasitaemia,
the expression of granzyme B and KLRG1 by splenic CD8+
T cells was enhanced rather than decreased in 4X compared
with 1X infected IgMi mice, suggesting that that CD8+ T
cell activation during repeated PbA infections was not directly
proportional to peripheral parasite burden (Figures 6B,E). In
contrast, the activation of splenic CD4+ T cell responses were
unaltered in 4X IgMi mice compared with corresponding 4X
infected WT mice (Figure S5).
Thus, collectively, our data suggest that secreted antibody is
required during the repeated rounds of infection to modulate
the B cell compartment and suppress pathogenic CD8+ T cell
responses to establish infection-induced resistance to ECM.
DISCUSSION
In this study, we have shown that multiple rounds of PbA parasite
exposure lead to the incremental development of ECM resistance
in otherwise susceptible C57BL/6 background mice. Our results,
therefore, appear to recapitulate the development of naturally
acquired resistance to CM in humans inmalarial endemic regions
(4). Although protection against ECM was associated with the
gradual control of peripheral parasite burdens and reduced
parasite accumulation within the brain, sterile immunity was
not achieved.
In this model system infection-induced protection against
ECM appeared to depend upon the inhibition of memory CD8+
T cell reactivation, rather than a generalized dampening of
inflammation. Indeed, splenic CD4+ T cell responses and plasma
pro-inflammatory cytokine levels were comparable or increased
in 4X infected mice compared with 1X infected mice. Granzyme
B expression by CD8+ T cells was reduced in 4X infected mice
compared with 1X infected mice but IFN-γ production was
not significantly affected by the number of infections. It has
been shown that IL-12/IL-18 and IL-15 differentially control
IFN-γ production and granzyme B expression by reactivating
memory CD8+ T cells, respectively (45). Consequently, it is
foreseeable that modified memory CD8+ T cell reactivation
during 4X infection was caused by alterations in the levels of IL-
15. However, it is possible that lowered peripheral parasitaemia
in 4X infected mice also contributed to alterations in CD8+ T
cell reactivation.
It is probable that the inhibition of CD8+ T cell pathogenic
responses in the brain of 4X infected mice was caused by the
modulation of CD8+ T cell immune activation within the spleen,
leading to reduced migration of less-pathogenic CD8+ T cells to
the brain in 4X infected mice. Nevertheless, our transcriptomics
analyses also suggest that many of the tissue signals, such as
endothelial cell cross presentation of parasite antigen, which are
necessary for CD8+ T cells to arrest, mediate damage to the
blood brain barrier and provoke ECM (32, 46, 47), were also
down regulated in the brains of 4X infected mice. This was likely,
in part, due to the fact that parasite accumulation appeared,
through qualitative assessment, to be reduced / prevented in
brains of 4X compared with 1X infected mice. Indeed, it has
previously been shown that pathogenic CD8+ T cell activation
in the brain during PbA infection depends upon a threshold
level of parasite accumulation and parasitic antigen in the brain
(48). Interestingly, our transcriptomics analyses suggests that
infection-induced dampening of intracerebral immune responses
and resistance to ECM mirrors processes that specify genetic
resistance to ECM, and those associated with avirulent parasite
infections (49–51). The datasets generated in this study will be
useful resources to identify other gene candidates that control
resistance to ECM during PbA infection.
In terms of the infection-induced processes that provided
protection against ECM, we have shown the critical non-
redundant role of antibody. IgMi mice, which were unable
to produce secreted antibody or undergo class switching (21,
22), developed hyperactive splenic and intracerebral CD8+ T
cell responses during 4X infection and consequently failed
to acquire infection-induced resistance to ECM. Antibody
responses to the immunodominant antigen MSP-119 did not
correlate with resistance to ECM; however, total anti-parasite
Ab responses developed more gradually over repeated infections
and were eventually maintained, at least short term, between
3rd and 4th infections. These observations are in agreement
with previous studies showing that anti- PbMSP1 antibody titres
did not correspond with vaccine induced protection against
PbA (30). Also, they are consistent with studies in human
malaria, showing that exposure-induced protection against P.
falciparum is associated with the gradual accumulation of B cells
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FIGURE 6 | IgMi mice do not develop infection-induced resistance to ECM. (A–F) IgMi mice and WT littermate controls were infected with PbA (104 pRBCs i.v.) or left
uninfected. Mice were treated (i.p.) with chloroquine and artesunate from day 5 or 6 post each infection, and re-infections were performed after a minimum interval of
30 days following cessation of drug treatment. (A) Kinetics of ECM development, shown as percentage of survival of mice. (B) Peripheral parasitaemia (% of pRBCs).
(C) Left, Representative flow cytometric plots (gated on live CD45+CD3−CD19+ cells), right, the frequencies of non-switched (IgM+ IgD+ and IgM− IgD+) and
switched (IgM+ IgD−, and IgM− IgD−) splenic CD19+ B cells. (D) Expression of CD138, CD80, CD11c, PDCA1, PDL-1 and MHC II by CD19+ splenic B cells from 1X
(Continued)
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FIGURE 6 | infected and 4X infected WT and IgMi mice. (E,F) Activation phenotype of (E) splenic and (F) brain accumulating CD8+ T cells. (B,C,E,F) Results are the
mean ± SD of the group. (A,B) N = 7–8 per group, pooled from two independent experiments. (C) N = 3–4 per group, representative of two independent
experiments. (E,F) N = 5–8 per group, pooled from two independent experiments. (B,E,F) Statistical analyses were performed with Kruskal-Wallis test with Dunn’s
multiple comparisons test or with one-way ANOVA with Tukey’s test depending on normality of data (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, and p <
0.05 denoted as follows *, WT 1X v IgMi 1X, ∼, WT 4X v IgMi 1X, #, WT 4X v IgMi 4X,
†
, IgMi 1X v IgMi 4X). (C) Statistical analysis by Student’s t-test, with Welch’s
correction for indicated groups (p < 0.05 denoted by #, ∼, ‡ for the indicated groups).
with different specificities (12, 52, 53). The role of maintained
antibody in infection-induced protection to ECM is supported by
seroepidemiological studies in humans, where the level of anti-
P. falciparum antibody prior to the malaria season, but not after
the malaria season, correlated with protection against clinical
disease (12, 52).
The fact that IgMi mice failed to develop resistance to ECM
but we were unable to protect 1X infectedmice by passive transfer
of plasma from 4X infected mice may suggest that we failed
to transfer enough antibody in our experiments to promote
protection. Whilst we cannot fully discount this possibility,
passive transfer of plasma from 4X infected mice did lead to
significant reductions in parasite levels during the course of 1X
infection. Moreover, we transferred higher amounts of antibody
(four injections of 500 µl of plasma with Ab end point titer
>1 × 106 during the course of infection) than has been used
to significantly reduce parasite burdens and protect mice from
other malarial species, such as P. yoelii and P. chabaudi (31,
54). The inability of passively transferred anti-parasite Ab to
provide protection against P. berghei infection has previously
been described (54) and, to date, we are unaware of any other
study where passive transfer of antisera has promoted resistance
against ECM in primary PbA infected mice. Thus, our data
argue that repeated PbA infection promotes generation and
maintenance of anti-parasite antibodies that establish changes
in the immune system over the course of repeat infections that
provide protection against ECM, and which cannot be easily
recapitulated by acute administration of high titres of antibody
to primary infected mice.
There are various potential ways through which antibody
could educate the immune system during the course of
repetitive Plasmodium infections to inhibit CD8+ T cell
activity and promote resistance to ECM. Antibody, in the
form of immune complexes and via triggering Fc receptors,
or through activating complement, can significantly modulate
APC activation, cytokine production and antigen presentation
(41–44). There is accumulating evidence that memory CD8+
T cell reactivation can be substantially influenced by the
repertoire, duration and level of cytokine production, co-
stimulation, and nature of antigen presentation from different
APC populations (45, 55–57). For example, in viral infections
antibody-antigen immune complexes can extend the duration of
antigen presentation post-clearance of infection, which although
not affecting the ultimate magnitude of the maintained memory
CD8+ T cell population, significantly influences memory
CD8+ T cell reactivation (41). Notably, modulation of innate
cell phenotype and function can persist post-clearance of
Plasmodium infection (58), and the duration of these changes
have been linked to the maintenance of anti-parasite antibody
(59). It has also been reported that the CD11c+ DC population
is altered in mice repeatedly infected with PbA and that this
contributes to resistance to ECM (60). Thus, antibody may
extend infection-induced alterations in innate cell activity and
antigen presentation following clearance of infection, as well as
influencing APC reactivity in the acute period during challenge
infections, ultimately affecting memory CD8+ T cell reactivation.
Although we focussed on anti-parasite IgG in this study, it has
been shown anti-malarial memory B cell populations maintain
the capacity for IgM production (61). IgM through binding
to TOSO on B cells has been shown to indirectly regulate
CD8+ T cell activation during PbA infection (62). Thus, secreted
IgM and IgG isotypes may play a role in regulating memory
CD8+ T cell reactivation during repeated Plasmodium spp.
infection. Defining precisely how antibody, and importantly
gradual acquisition of different specificities of anti-parasite Ab,
influence the immune environment to repress pathogenic CD8+
T cell responses during 4X PbA infection to promote resistance
to ECM should be the subject of detailed investigations in further
studies. For example, the role of the Fcgamma RIIb receptor,
which is expressed on CD8+ T cells and which influences
memory CD8+ T cell activation during Listeria monocytogenes
infection (63), could be examined by studying whether Fcgamma
RIIb deficient mice develop infection-inducedresistance to ECM.
Whilst we believe antibody was key for protection in our
infection-drug cure model, it was of interest that infection-
induced protection against ECM also corresponded with the
formation of atypical B cell populations in the spleen, and that
development of these atypical B cell populations was abrogated
in repeatedly infected IgMi mice. The function of atypical B
cell populations during malaria, which have principally be
defined as memory B cells (12–15), but in our model could
also include non-conforming plasmablasts and plasma cells
(16, 33, 34), is still unclear. Very recently it has been shown that
atypical B cells are short-lived activated B cells during malaria
that form as part of a natural ongoing B cell response (64).
Evidence suggests atypical B cells may be protective through
anti-parasite Ab production (15) or via immunoregulatory
activity, suppressing damaging inflammation (14, 17–19),
or they are dysfunctional, impeding generation of long-lived
humoral immunity or contributing to autoimmunity (12–16, 19).
We found that transitory depletion of the majority of atypical B
cells as well as CD19+IgM+IgD+ cells [which include classical
regulatory B cells (38)] immediately prior to and during 4X
infection by anti-CD20 mAb administration failed to reverse
infection-induced resistance to ECM. This showed that atypical
B cells and regulatory B cell populations (as well as other classical
B cell populations) were not necessary for active protection
to ECM during the on-going 4X infection, at least when the
duration between 3 and 4X infection was relatively short. This
result contrasts with the previous observation that adoptive
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transfer of IL-10 expressing Bregs from ECM resistant multiply
infected mice promotes resistance to ECM in primary infected
mice (40). Whilst the reason for our conflicting data is unclear
it is probable that although high numbers of IL-10 expressing
Bregs can be sufficient for protection against ECM following
adoptive transfer, they are not necessary for physiological active
protection in the context of a full working memory immune
compartment. In agreement with this, we found that IL-10R
blockade, although slightly improving parasite control, did
not affect the resistance of 4X infected WT mice to ECM.
Nevertheless, we cannot discount the possibility that the atypical
B cell populations, in concert with antibody, may play a role
in gradually modulating the immune system during repetitive
infections, eventually conditioning an immunological state that
provides resistance to ECM in 4X infected mice. Indeed, B cells
can undertake APC functions and can directly tolerise CD8+ T
cells (65). The overall role of B cells in establishing anti-disease
immunity could be examined in the future using uMT mice.
In summary, in this model of repeated parasite exposure
we have shown that infection-induced resistance to ECM
was associated with the repression of memory CD8+ T cell
reactivation during 4X infection. Resistance to ECM and
inhibition of pathogenic memory CD8+ T cell responses was
ablated in mice unable to produce secreted antibody but
protection against ECM could not be recapitulated solely
by the transfer of high titer anti-parasite antibody prior to
primary infection, and protection during the fourth infection
was not reversed by active depletion of the majority of the B
cell compartment. Thus, our results suggest that anti-parasite
Ab may gradually orchestrate and maintain changes in the
immunological environment that eventually attenuate splenic
memory CD8+ T cell reactivation in repeatedly infected mice.
Although the contribution of CD8+ T cells in the pathogenesis of
HCM remains controversial, there is some evidence that activated
CD8+ T cells may play a role in severe malarial disease (66, 67).
Consequently, our results provide insight into the mechanisms of
protection to ECM and may have implications for studying the
basis of infection-induced resistance to severe malarial disease
and specifically cerebral malaria in humans.
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Figure S1 | (A) Peripheral parasitaemia (% of pRBCs) ± SD in 3X and 4X infection
groups from day 8 post infection (n = 2–10 per time point). (B) Representative H &
E stained brain sections demonstrating presence and absence of hemorrhage,
packed vessels and oedema in 1X and 4X infected mice on day 8 post infection.
(C) Representative immunofluorescence stained cortical brain sections
demonstrating presence and absence of pRBCs (green) in the CD31+
cerebrovascular (red) of 1 and 4X infected mice on day 8 post infection. Nuclei
were counterstained with dapi (blue).Scale bar 25µm.
Figure S2 | (A–D) Perfused whole brains were removed from 4X infected and
age-matched 1X infected C57BL/6 mice on day 8 p.i. (when 1X developed ECM),
and age-matched nal¨ve mice, for microarray analysis. (A) K-means and
hierarchical clustering of differentially expressed genes in 4X mice vs. uninfected
mice and 1X mice vs. uninfected mice. Each probe-set expression level was
normalized to the naïve average. (B) Gene ontology analysis identifying enriched
biological processes within each gene cluster, identified within DAVID
bioinformatics database. (C) Full size defense response and (D) regulation of
apoptosis gene ontology pathways differentially expressed in brains of 1X and 4X
infected mice. N = 6 per group. Results are generated from the pooled array data
from brains taken from two independent experiments.
Figure S3 | (A,B) Perfused whole brains were removed from 4X infected and
age-matched 1X infected C57BL/6 mice on day 8 p.i. (when 1X developed ECM),
for microarray analysis. Ingenuity analysis identified (A) IL-6- and (B)
IFN-γ-controlled gene networks as two major pro-inflammatory gene networks
downregulated in the brains of 4X infected mice compared with 1X infected mice
(green color represents down-regulated gene expression and red color represents
up-regulated gene expression). (C) Nanostring validation of expression of selected
genes in whole brains of 1 and 4X infected mice on day 8 of infection (presented
as fold change in expression compared with nal¨ve brains). (A,B) N = 6 per group.
Results are generated from the pooled array data from brains taken from two
independent experiments. (C) N = 5 per group, from two pooled experiments.
Statistical analysis by Student’s t-test, with Welch’s correction (∗p ≤ 0.05, ∗∗p ≤
0.01, ∗∗∗∗p ≤ 0.0001).
Figure S4 | (A,B) C57BL/6 mice were injected (i.p) one day prior to 4X infection
and on days 2, 5, 8, 11 of infection, with either (250 µg) anti-CD20 mAb or (250
µg) control anti-ragweed mAb. Frequencies of granzyme B expressing CD8+ T
cells in (A) the spleen and (B) the brain on day 8 post infection of age matched
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nal¨ve, 1X infected and 4X infected mice, that received anti-CD20 mAb or
anti-ragweed mAb. (C) Cytokine bead array of plasma cytokine IL-10 levels in 4X,
1X infected mice and aged matched uninfected C57BL/6 mice. (D) C57BL/6 mice
were injected (i.p) one day prior to the 4X infection and on every other day of 4X
infection with anti-IL-10R mAb or PBS. Kinetics of ECM development shown as
percentage survival of mice. (A–C) Results are the mean ± SD of the group. (A,B)
N = 4–8 per group, pooled from two independent experiments. (C) N = 4–7 per
group, pooled from two independent experiments. (D) N = 9 per group, pooled
from two independent experiments. Statistical analyses were performed with
Kruskal-Wallis test with Dunn’s multiple comparisons test (∗p ≤ 0.05, ∗∗p ≤ 0.01
and ∗∗∗p ≤ 0.001).
Figure S5 | IgMi mice and WT littermate controls were infected with PbA (104
pRBCs i.v.) or left uninfected. Mice were treated (i.p.) with chloroquine and
artesunate from day 5 or 6 post each infection, and re-infections were performed
after a minimum interval of 30 days following cessation of drug treatment.
Activation phenotype of splenic CD4+ T cells in the different groups of IgMi and
WT littermate mice. N = 2–4 per group, representative of two independent
experiments. Statistical analyses were performed with Kruskal-Wallis test with
Dunn’s multiple comparisons test (∗p ≤ 0.05).
Supplementary Table 1 | C57BL/6 mice were infected with PbA (104 pRBCs i.v.)
or left uninfected. Mice were treated (i.p.) with chloroquine and artesunate as
shown in Figure 1A, and re-infections were performed after a minimum interval of
30 days following cessation of drug treatment. Table shows the day post infection,
number of mice, mean peripheral parasitaemia (% of pRBCs) ± SD in different
infection groups. Results are pooled from two experiments for the 1X, 2X, and 3X
infection and from 3 experiments for the 4X infection.
Supplementary Table 2 | List of differentially expressed genes included within
Figure 2 and Figure S2.
Supplementary Table 3 | Genes in Supplementary Table 1 filtered to identify
genes differentially expressed between 4X and 1X brains.
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